[Fundamental and clinical studies of cefotaxime in neonates and immature infants]
Related Experiment Videos
Insights
Cefotaxime (CTX) demonstrates effective treatment and prophylaxis for neonatal infections. Recommended dosages vary by infant age, showing good clinical efficacy with no observed adverse reactions.
Area of Science:
- Pediatric Pharmacology
- Neonatal Infectious Diseases
- Antibiotic Pharmacokinetics
Background:
- Neonates and immature infants often face unique challenges in managing infections due to immature organ systems.
- Cefotaxime (CTX) is a third-generation cephalosporin antibiotic with broad-spectrum activity, frequently used in pediatric populations.
- Establishing optimal dosing regimens for antibiotics in neonates is critical for efficacy and safety.
Observation:
- Serum concentrations of CTX were measured 30 minutes and 6 hours post-intravenous injection (20 mg/kg) across different neonatal age groups (0-3 days, 4-7 days, 8+ days).
- Mean serum concentration half-lives varied by age, ranging from 1.5 to 3.2 hours.
- Urinary recovery rates of CTX ranged from 0.8% to 78.0% within 6 hours post-administration.
Findings:
- Recommended intravenous CTX dosages of 20 mg/kg every 12 hours for 0-3 day olds, every 8 hours for 4-7 day olds, and every 6-8 hours for 8+ day olds.
- Achieved adequate serum concentrations and half-lives supporting therapeutic efficacy.
- Demonstrated 100% cure rates in treated cases of sepsis, urinary tract infections, and fever of unknown origin.
- No adverse reactions were reported during the study.
Implications:
- The study supports the use of cefotaxime for treating and preventing infections in neonates and immature infants.
- Age-specific dosing recommendations are crucial for optimizing cefotaxime therapy in this vulnerable population.
- The favorable efficacy and safety profile suggest CTX is a valuable therapeutic option for neonatal infections.
Abstract:
Cefotaxime (CTX) was used in the treatment and prophylaxis of infections in neonates and immature infants. The following results were obtained. 1. Mean serum concentrations (bioassay) 30 minutes after a single intravenous injection of about 20 mg/kg of CTX were 44.5 mcg/ml in neonates and 47.2 mcg/ml in immature infants aged 0-3 days, 45.8 mcg/ml in neonates and 56.4 mcg/ml in an immature infant aged 4-7 days and 40.6 mcg/ml in neonates and 38.1 mcg/ml in immature infants aged 8 or more days. Six hour values were respectively 10.9 mcg/ml, 17.0 mcg/ml, 4.6 mcg/ml, 13.4 mcg/ml, 3.8 mcg/ml and 2.7 mcg/ml. 2. Mean serum concentration half-lives were 3.0 hours in neonates and 3.2 hours in immature infants aged 0-3 days, 1.8 hours in neonates and 3.2 hours in an immature infant aged 4-7 days, and 1.5 hours in neonates and 1.6 hours in immature infants aged 8 or more days. 3. Urinary recovery rates were 0.8-78.0% for 0-6 hours after treatment. 4. Adequate clinical efficacy can be expected by the intravenous injection of CTX in doses of 20 mg/kg 2 times daily, every 12 hours, in neonates and immature infants aged 0-3 days, 20 mg/kg 3 times daily, every 8 hours, in neonates and immature infants aged 4-7 days, and 20 mg/kg 3 to 4 times daily, every 6-8 hours, in neonates and immature infants aged 8 or more days. 5. The clinical efficacy of CTX was good in all 4 cases of sepsis (including suspected case), excellent in 1 case of urinary tract infection, and good in all 4 cases of fever of unknown origin for a cure rate of 100%. 6. Adverse reactions were not noted in any cases.